Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#65 Niacin added to statins for cardiovascular disease (CVD)? 1 + 1 = 1


CLINICAL QUESTION
QUESTION CLINIQUE
In patients with CVD and low HDL levels, does adding niacin to statin therapy decrease future cardiovascular events?


BOTTOM LINE
RÉSULTAT FINAL
In patients with CVD on conventional therapy, adding niacin does not reduce cardiovascular events. Among lipid treatments, only statin monotherapy has strong evidence for CVD prevention (regardless of lipid levels).



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
HPS2-THRIVE:1 Randomized Controlled Trial (RCT) of 25,673 patients (mean age 65, 83% male) with previous CVD taking simvastatin 40 mg +/- ezetimibe 10 mg. 
  • Randomized to niacin extended-release 2,000 mg plus laropiprant 40 mg or placebo for ~4 years. 
  • No difference in primary outcome (combined CVD): 13.2% versus 13.7%. 
  • Niacin increased risk of: 
    • Serious adverse events: 55.6% versus 52.7%Number Needed to Harm (NNH)=35. 
    • Discontinuation due to adverse events: 25.4% versus 16.5%NNH=12. 
  • Niacin improved lipids versus placebo. 
    • LDL -0.25 mmol/LHDL +0.16 mmol/LTriglycerides -0.37 mmol/L. 
Meta-analysis2 of 11 RCTs (including HPS2-THRIVE) of 35,301 patients: 
  • No difference between niacin versus placebo on death, non-fatal myocardial infarction or stroke. 
The Coronary Drug Project RCT:3 Only trial to demonstrate cardiovascular benefit of niacin over placebo. 
  • Enrolled men 30-64 years-old with prior myocardial infarction. 
  • Limitations: Over 40 years old, before statins and other proven secondary prevention therapies (aspirin, ACE inhibitors, beta-blockers, etc). 
Context:  
  • Surrogate outcomes like lipids can be misleading.4 
    • The drug torcetrapib reduced LDL 25% and increased HDL 72%, but increased CVD and mortality.5 
    • Statins improve CVD outcomes irrespective of initial lipid levels6 or the degree of LDL reduction.7 
  • Good evidence demonstrates that statins reduce CVD, particularly in secondary CVD prevention.8 
  • Canadian cardiovascular society guidelines9 recommend treating to lipid targets (LDL, non-HDL, and ApoB), including adding ezetimibe, bile acid resins, or PCSK9 inhibitors to statins if needed. 
    • Niacin recommended only if LDL goal not achieved despite all of the above. 
  • American guidelines10 recommend against niacin due to risk of serious harm with no clinical benefit. 
  • Canadian Primary Care Lipid Guidelines do not recommend niacin.11   


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Michael R Kolber BSc MD CCFP MSc

1. The HPS2-TRIVE Collaborative Group. N Engl J Med. 2014; 371:203-12

2. Keene D, Price C, Shun-Shin MJ, et al. BMJ. 2014; 349:g4379.

3. The Coronary Drug Project Research Group. JAMA. 1975; 231:360-81.

4. Hayward RA, Krumholz HM. Circulation Cardiovasc Qual Outcomes. 2012; 5:2-5.

5. Barter PJ, Caulfield M, Eriksson M, et al. N Engl J Med. 2007; 357:2109-22.

6. Heart Protection Study Collaborative Group. Lancet. 2002; 360:7-22.

7. Hayward RA, Hofer TP, Vijan S. Ann Intern Med. 2006; 145:520-30.

8. Baingent C, Keech A, Kearney PM, et al. Lancet. 2005; 366:1267-78

9. Anderson TJ, Gregoire J, Pearson GJ, et al. Can J Cardiol. 2016; 32(11): 1263-82.

10. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. J Am Coll Cardiol. 2016; 68:92-125.

11. Allan GM, Lindblad AJ, Comeau A, et al. Can Fam Physician. 2015; 61:857-67.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 22/07/2016

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: New evidence; Bottom Line: Slight change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks